Cervical cancer drugs market is anticipated to grow at a significant CAGR during the forecast period. The growth of the market for these drugs is majorly attributed to the growing prevalence of cervical cancer. Adding to this, human papillomavirus (HPV) is a major causative factor for cervical cancer, which is usually acquired through sexual transmission; this factor too is anticipated to drive the market for cervical cancer drugs. There are more than 100 strains of HPV, out of which 13 are high risk or cancerous. Cervical cancer has a high mortality rate which can be reduced by diagnosis and prevention. Therefore, substantial government initiatives, coupled with the launch of targeted therapies are the major factors that will create awareness and thus the early diagnosis for cervical cancer among the global population.
As the disease growth is usually slow, precancerous changes provide possibilities for prevention and treatment. Although most cases are diagnosed at almost last stages of disease growth due to the lack of awareness or inaccessibility to diagnostic facilities. Thus, the challenge of early diagnosis needs to be addressed so as to reduce the global healthcare burden of the disease. Further, regulatory approval for the various treatment drugs is also likely to spur the market growth. For instance, Avastin (bevacizumab) was approved for the treatment of cervical cancer in 2014. This marked the arrival of biologics in this treatment landscape. Avastin was approved in Europe and Japan in 2015 and 2016, respectively. Following this, the FDA approved Keytruda (pembrolizumab) in 2018.
To Request a Sample of our Report on Cervical Cancer Drugs Market: https://www.omrglobal.com/request-sample/cervical-cancer-drugs-market
Market Coverage
- The market number available for – 2021-2029
- Base year- 2021
- Forecast period- 2023-2029
Segment Covered-
- By Cancer Type
- By Product Type
Regions covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape: Pfizer Inc., F. Hoffman La-Roche AG, and GlaxoSmithKline plc, among others.
Cervical Cancer Drugs Market Report by Segment
By Cancer Type
- Squamous Cell Cancer
- Adenocarcinoma
By Product Type
- Prevention
- Cervarix
- Gardasil 9
- Recombinant Human Papillomavirus (HPV) Bivalent Vaccine
- Recombinant Human Papillomavirus (HPV) Nonavalent Vaccine
- Recombinant Human Papillomavirus (HPV) Quadrivalent Vaccine
- Others
Treatment
- Avastin
- Bevacizumab
- Bleomycin
- Blenoxane
- Others
A full Report of Cervical Cancer Drugs Market is Available @ https://www.omrglobal.com/industry-reports/cervical-cancer-drugs-market
Cervical Cancer Drugs Market by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East and Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/cervical-cancer-drugs-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
